CROs/Service Providers

ICON acquires Mapi Group

Monday, July 31, 2017

Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has acquired the Mapi Group, a Patient-Centered Health Outcomes Research and Commercialization company.

[Read More]

LabCorp to acquire Chiltern for $1.2B in cash

Monday, July 31, 2017

LabCorp, a global life sciences company, and Chiltern, a specialty CRO, announced that LabCorp will acquire Chiltern pursuant to a definitive agreement with Chiltern’s shareholders in an all-cash transaction valued at approximately $1.2 billion. Once the transaction is complete, Chiltern will become part of LabCorp’s Covance segment.

[Read More]

Initial results from Dana-Farber Cancer Institute personalized neoantigen vaccine published

Friday, July 7, 2017

Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has announced the publication of an article in Nature presenting initial feasibility, safety, immunogenicity and clinical outcomes for a personalized neoantigen vaccine in patients with adjuvant melanoma. The article entitled ‘An immunogenic personal neoantigen vaccine for patients with melanoma’ (DOI 10.1038/nature22991) demonstrates the validity of the neoantigen vaccine approach as an effective immunotherapy.

[Read More]

INC Research launches Psychiatry Catalyst Site Network

Thursday, July 6, 2017

INC Research Holdings, Inc., a leading, global phase I to IV contract research organization, has announced the launch of the Company’s Psychiatry Catalyst Site Network as part of its Catalyst program introduced in 2016 to strengthen collaborations with clinical research sites worldwide. The ultimate goal of the program is to enhance patient focus and optimize study delivery to drive improved predictability and increased efficiency for customers.  INC selected 32 high-performing clinical research sites to participate in the initial launch of the Psychiatry Catalyst Site Network, which was formed to respond to the rapid growth and strong pipeline of psychiatric studies. The Psychiatry Catalyst Site Network joins INC’s existing networks in place in support of Oncology and Vaccine clinical research.

[Read More]